DJIA 17,665.15 68.80 0.39%
NASDAQ 4,985.29 26.82 0.54%
S&P 500 2,064.59 6.95 0.34%
market minute promo

Seattle Genetics (NASDAQ: SGEN)

47.68 0.81 (1.73%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

SGEN $47.68 1.73%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $47.44
Previous Close $46.87
Daily Range $47.09 - $47.77
52-Week Range $30.05 - $49.84
Market Cap $6.0B
P/E Ratio -71.02
Dividend (Yield) $0.00 (0.0%)
Volume 113,398
Average Daily Volume 869,854
Current FY EPS -$0.80

Sector

Healthcare

Industry

Drug Makers

Seattle Genetics (SGEN) Description

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Website: http://www.seattlegenetics.com/

News & Commentary

Is This Why the Street Keeps Doubting Gilead Sciences, Inc.?

Gilead Sciences looks like a screaming buy right now based on its fundamentals. But the Street apparently doesn't think so. Here's why.

How To Make Money In Small To Nano-Cap Biotech

Interesting SGEN Put And Call Options For August 21st

Seattle Genetics' Collaborative Approach To Fighting Cancer Makes It A Buy

Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the Intern

Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma

The Zacks Analyst Blog Highlights: Regeneron, Vertex, Celgene, Seattle Genetics and SAGE Therapeutic

The Zacks Analyst Blog Highlights: Regeneron, Vertex, Celgene, Seattle Genetics and SAGE Therapeutics - Press Releases

Seattle Genetics-Unum Therapeutics Tie Up for Cancer Drugs - Analyst Blog

3 Stocks Improving Performance Of The Drugs Industry

Seattle Genetics Announces Data Presentations at ASCO Related to ADCETRIS in AETHERA Post-Transplant

Seattle Genetics Announces Data Presentations at ASCO Related to ADCETRIS in AETHERA Post-Transplant Consolidation Setting

Seattle Genetics Larger Than S&P 500 Component Tenet Healthcare

Seattle Genetics Announces Clinical Data Presentations from Multiple Antibody-Drug Conjugate Program

Seattle Genetics Announces Clinical Data Presentations from Multiple Antibody-Drug Conjugate Programs

See More SGEN News...

SGEN's Top Competitors

SGEN $47.68 (1.73%)
Current stock: SGEN
AMGN $151.88 (0.18%)
Current stock: AMGN
GILD $117.32 (1.62%)
Current stock: GILD
BIIB $399.55 (0.84%)
Current stock: BIIB